Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sulanemadlin alone and with cytarabine in R/R AML or MDS
NCT02909972Phase 1Completed
- Sponsor
- Rein Therapeutics
- Start
- Sep 2016
- Primary completion
- Apr 2019
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of sulanemadlin in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (2 arms), sponsored by Rein Therapeutics. Primary endpoints: Safety and Tolerability of ALRN-6924 alone and in combination with cytarabine and Maximum Tolerated Dose. Started Sep 2016; status: completed.
02
Drugs
sulanemadlin
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT02909972.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02909972.